These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36649877)

  • 1. JAK inhibitors and autoimmune rheumatic diseases.
    Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
    Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.
    Tanaka Y; Luo Y; O'Shea JJ; Nakayamada S
    Nat Rev Rheumatol; 2022 Mar; 18(3):133-145. PubMed ID: 34987201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK Inhibitors: Prospects in Connective Tissue Diseases.
    You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
    Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibitor: Introduction.
    Raychaudhuri SP; Raychaudhuri SK
    Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
    Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
    Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease.
    Gupta S; Yamada E; Nakamura H; Perez P; Pranzatelli TJ; Dominick K; Jang SI; Abed M; Martin D; Burbelo P; Zheng C; French B; Alevizos I; Khavandgar Z; Beach M; Pelayo E; Walitt B; Hasni S; Kaplan MJ; Tandon M; Magone MT; Kleiner DE; Chiorini JA; Baer A; Warner BM
    Ann Rheum Dis; 2024 Jul; 83(8):1034-1047. PubMed ID: 38527764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Jakinibs in systemic lupus erythematosus: progress and prospects.
    Mok CC
    Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
    Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
    Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors for the treatment of autoimmune and inflammatory diseases.
    Jamilloux Y; El Jammal T; Vuitton L; Gerfaud-Valentin M; Kerever S; Sève P
    Autoimmun Rev; 2019 Nov; 18(11):102390. PubMed ID: 31520803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [JAK inhibition in the treatment of inflammatory rheumatic diseases].
    Šenolt L
    Vnitr Lek; 2023; 69(3):181-188. PubMed ID: 37468313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
    Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
    Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
    Alunno A; Padjen I; Fanouriakis A; Boumpas DT
    Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update.
    Chuprin J; McCormack L; Richmond JM; Rashighi M
    Expert Rev Clin Immunol; 2022 Mar; 18(3):263-272. PubMed ID: 35209781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of targeting JAK/STAT signal transduction pathways for vasculitis.
    Huo RX; Yang YT; Yang Y; Huo XC; Meng DL; Huang RJ; Huang YJ; Lin JY; Zhu X; Wei CC; Huang XX
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):1864-1872. PubMed ID: 38497869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren's Syndrome.
    Charras A; Arvaniti P; Le Dantec C; Arleevskaya MI; Zachou K; Dalekos GN; Bordon A; Renaudineau Y
    Clin Rev Allergy Immunol; 2020 Apr; 58(2):182-193. PubMed ID: 31165348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
    Fragoulis GE; McInnes IB; Siebert S
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i43-i54. PubMed ID: 30806709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.